Clinical Trial Update: Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial of mepolizumab in moderate to severe atopic dermatitis was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Dermatitis, Atopic | Phase 2 | Status: TERMINATED | Results posted: 2018-12-26